BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11418508)

  • 1. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
    Thorburn CE; Edwards DI
    J Antimicrob Chemother; 2001 Jul; 48(1):15-22. PubMed ID: 11418508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
    Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
    Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
    Madaras-Kelly KJ; Demasters TA
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
    Visalli MA; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():107-10. PubMed ID: 10824041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
    Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
    J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
    Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
    J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
    Lister PD; Sanders CC
    Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
    Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.
    Dalhoff A
    Drugs; 1995; 49 Suppl 2():194-6. PubMed ID: 8549301
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.